{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:36:36Z","timestamp":1770489396107,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.clml.2021.09.008","type":"journal-article","created":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T19:36:44Z","timestamp":1631389004000},"page":"121-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine"],"prefix":"10.1016","volume":"22","author":[{"given":"Alexey V.","family":"Danilov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Habte A.","family":"Yimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4395-394X","authenticated-orcid":false,"given":"Michael A.","family":"Boxer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5085-6905","authenticated-orcid":false,"given":"Sunil","family":"Babu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Mun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Trask","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony S.","family":"Masaquel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff P.","family":"Sharman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.09.008_bib0001","doi-asserted-by":"crossref","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.09.008_bib0002","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2021.09.008_bib0003","unstructured":"Key Statistics for Chronic Lymphocytic Leukemia: American Cancer Society. https:\/\/www.cancer.org\/cancer\/chronic-lymphocytic-leukemia\/about\/key-statistics.html; 2020. Accessed 13 January 2021."},{"key":"10.1016\/j.clml.2021.09.008_bib0004","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1080\/10428190500244183","article-title":"Quality of life in chronic lymphocytic leukemia: a neglected issue","volume":"46","author":"Molica","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.09.008_bib0005","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1007\/s11136-015-1039-y","article-title":"Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study","volume":"24","author":"Holtzer-Goor","year":"2015","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clml.2021.09.008_bib0006","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10428190701724785","article-title":"Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia","volume":"49","author":"Thurmes","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.09.008_bib0007","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3324\/haematol.2013.096792","article-title":"Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials","volume":"99","author":"Goede","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.09.008_bib0008","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.31554","article-title":"Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib","volume":"124","author":"Gordon","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.09.008_bib0009","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2017-03-772285","article-title":"In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI","volume":"129","author":"Rigolin","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.008_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00277-014-2161-6","article-title":"Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL\/SLL in the Netherlands","volume":"94","author":"van den Broek","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.09.008_bib0011","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2007-12-129379","article-title":"Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.008_bib0012","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","article-title":"Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.09.008_bib0013","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/0284186X.2016.1205217","article-title":"Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL","volume":"55","author":"Hillmen","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clml.2021.09.008_bib0014","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1097\/HS9.0000000000000336","article-title":"Long term follow-up data and health-related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 trial of the GCLLSG)","volume":"4","author":"Kutsch","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2021.09.008_bib0015","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1182\/blood-2019-126542","article-title":"Rapid improvement of patient-reported outcomes with venetoclax plus obinutuzumab in patients with previously untreated CLL and coexisting conditions: a prospective analysis from the CLL14 Trial","volume":"134","author":"Al-Sawaf","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.008_bib0016","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.008_bib0017","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2021.09.008_bib0018","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/10428194.2020.1850719","article-title":"Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia","volume":"62","author":"Sharman","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.09.008_bib0019","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.008_bib0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2021.09.008_bib0021","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.008_bib0022","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12955-016-0475-x","article-title":"Development of an item bank for the EORTC Role Functioning Computer Adaptive Test (EORTC RF-CAT)","volume":"14","author":"Gamper","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.clml.2021.09.008_bib0023","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2007.06791.x","article-title":"Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients","volume":"139","author":"Shanafelt","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.09.008_bib0024","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.ejca.2006.08.016","article-title":"Equating EORTC QLQ-C30 and FACT-G scores and its use in oncological research","volume":"42","author":"Holzner","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2021.09.008_bib0025","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3109\/10428194.2011.649479","article-title":"Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial","volume":"53","author":"Else","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.09.008_bib0026","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/10428194.2016.1190966","article-title":"FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia","volume":"58","author":"Kutsch","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.09.008_bib0027","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0609.2004.00233.x","article-title":"Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr","volume":"72","author":"Holzner","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.09.008_bib0028","first-page":"2853","article-title":"Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia","volume":"21","author":"Pashos","year":"2013","journal-title":"Support Care Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021020371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021020371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:36Z","timestamp":1761871116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021020371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2152265021020371"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.09.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}